FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1147 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... October 30, 2020 Lo que deben saber las personas con cáncer de mama y... January 4, 2024 Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of... April 27, 2023 Load more HOT NEWS Color-Blind Groom Sees Color For First Time After Bride Surprises Him... Significantly Longer PFS with First-line Pembrolizumab for MSI-H/dMMR mCRC Girls Aloud members to join forces to raise money in Sarah... News digest – smoking ban, HPV and prostate cancer, genetic testing...
